|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Forgetful
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
In two unrelated UK families with APP 717 val-ile mutations there was early prominent memory impairment with dyscalculia proceeding to generalized cognitive impairment with a lack of insight.
|
8239283 |
1993 |
|
Forgetful
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
Transgenic mice carrying AD-causing mutations in APP develop spontaneous age-related beta-amyloid (A beta) deposition and memory impairment.
|
9052714 |
1997 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
The results suggest that plaque formation is not a necessary condition for the neuronal beta-APP(751) transgene-induced memory impairment, which may be caused by beta-APP overexpression, isoform misexpression, or elevated soluble Abeta.
|
11724968 |
2001 |
|
Forgetful
|
0.200 |
AlteredExpression
|
phenotype |
BEFREE |
Accumulations increased with age, and this was paralleled by decreased brain sizes on volumetric MRI, compared to age-matched and similar transgene-expressing APP wild-type mice, although, with these levels of transgenic expression we did not detect neuronal loss or significant memory impairment.
|
17112635 |
2008 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Here, in mice overexpressing wild-type human APP (hAPP(wt)) we found an early memory impairment, particularly in the water maze and to a lesser extent in the object recognition task, but beta-amyloid peptide (Abeta(42)) was barely detectable in the hippocampus.
|
19101630 |
2009 |
|
Forgetful
|
0.200 |
GeneticVariation
|
phenotype |
BEFREE |
Tg19959 mice carry human APP with two mutations and develop amyloid plaques and memory impairment starting at 3-4 months of age.
|
19914323 |
2010 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the amelioration ability of this compound against the in vivo memory impairment was further evaluated by APP-PS1 double transgenic mice model.
|
20412384 |
2010 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease.
|
21443906 |
2011 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Here, we show that Sod1 deficiency in an amyloid precursor protein-overexpressing mouse model (AD mouse, Tg2576) accelerated Aβ oligomerization and memory impairment as compared with control AD mouse and that these phenomena were basically mediated by oxidative damage.
|
22072713 |
2011 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that the sensorimotor gating is impaired with the progressing of AD phenotype, and its deficit may be correlated to cerebral Aβ neuropathology and memory impairment in the APP/PS1 transgenic mouse model of AD.
|
22595040 |
2012 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Here, we demonstrated that HFD markedly deteriorated memory impairment and increased β-amyloid (Aβ) oligomers as well as Aβ deposition in amyloid precursor protein (APP) transgenic mice, which was reversed by exposure to an enriched environment for 10 weeks, despite the continuation of HFD.
|
22197104 |
2012 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
In Tg2576 mice, knockdown by short hairpin RNA or knockout of the S100a9 gene significantly reduced the neuropathology, greatly improved the learning and memory impairment and reduced the amount of Aβ and APP-CTs by increasing neprilysin and decreasing BACE activity.
|
22301734 |
2012 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
In contrast, C57 APP/PS1 and SAMP8 wild type mice were inconspicuous in all of these tasks and properties except C57 APP/PS1 mice which showed motor memory impairment in the shuttle box task at 9 months old.
|
24095271 |
2013 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Tooth loss induces memory impairment and neuronal cell loss in APP transgenic mice.
|
23773908 |
2013 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
In mice, inhibition or siRNA-mediated silencing of PDK1 extends survival and reduces motor impairment following PrP(Sc) infection and in APP-transgenic mice reduces Alzheimer's disease-like pathology and memory impairment.
|
23955714 |
2013 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
The studied dendrimers did not reverse memory impairment in APP/PS1 mice following chronic administration; moreover, cationic G4mOS caused cognitive decline in nontransgenic mice.
|
24004423 |
2013 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Here, we show that xanthoceraside at doses of 0.08 and 0.32 mg/kg/d for 6 months significantly improved learning and memory impairment in APP transgenic mice assessed by the Y maze and novel object recognition tests.
|
24810883 |
2014 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Amyloid-β peptide 42 (Aβ42) is produced through the sequential proteolytic cleavage of APP by β- and γ-secretase and causes the synaptic dysfunction associated with memory impairment in Alzheimer's disease.
|
24373902 |
2014 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Exposure of isoflurane exhibited significant neuroapoptosis, Aβ generation, tau phosphorylation, and learning and memory impairment in APP/PS1 mice in the presence of Zn deficiency.
|
27586008 |
2016 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Although the primary causes of these disturbances are still under investigation, a growing body of evidence suggests that the amyloid precursor protein (APP) intracellular C-terminal fragment β (C99), generated by cleavage of APP by β-site APP cleaving enzyme 1 (BACE-1), is the primary cause of the endosome enlargement in AD and the earliest initiator of synaptic plasticity and long-term memory impairment.
|
28254759 |
2017 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Second, we used an APPswe/PS1E9 (APP/PS1) double transgenic mice to evaluate the amelioration ability of simvastatin against the memory impairment in vivo.
|
28528185 |
2017 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
We investigated the pharmacological potential of YY-1224 in β-amyloid (Aβ) (1-42)-induced memory impairment using cyclooxygenase-2 (COX-2) knockout (-/-) and APPswe/PS1dE9 transgenic (APP/PS1 Tg) mice.
|
28449688 |
2017 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
The results demonstrated that EA treatment ameliorated spatial learning and memory impairment in APP/PS1 mice and significantly reduced neuronal apoptosis and Aβ deposition in the hippocampus (P<0.05 and P<0.01).
|
30542451 |
2018 |
|
Forgetful
|
0.200 |
Biomarker
|
phenotype |
BEFREE |
Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice.
|
29253574 |
2018 |